Study to Assess the Efficacy and Safety of Dysport® in the Treatment of Chronic Plantar Fasciitis
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00447876 |
|
Recruitment Status :
Completed
First Posted : March 15, 2007
Results First Posted : June 23, 2017
Last Update Posted : November 22, 2019
|
Sponsor:
Ipsen
Information provided by (Responsible Party):
Ipsen
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This study will investigate the hypothesis that the analgesic effect of a single injection of Dysport (200 MU) induces a significant reduction of symptoms in chronic cases of plantar fasciitis.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Chronic Plantar Fasciitis | Biological: Botulinum toxin type A Drug: Placebo | Phase 2 Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 40 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | Double-blind, Placebo-controlled, Randomised, Multicentre Study on the Efficacy and Safety of a Single Injection of Botulinum Toxin A (200 Units Dysport®) in the Treatment of Chronic Plantar Fasciitis |
| Study Start Date : | July 2005 |
| Actual Primary Completion Date : | January 2009 |
| Actual Study Completion Date : | April 2009 |
| Arm | Intervention/treatment |
|---|---|
| Experimental: Botulinum type A toxin (Dysport®) |
Biological: Botulinum toxin type A
Botulinum type A toxin (Dysport®): 200 Units injected at the root of the plantar fascia
Other Name: AbobotulinumtoxinA (Dysport®) |
| Placebo Comparator: Placebo |
Drug: Placebo
0.9% sodium chloride: 2 ml injected at the root of the plantar fascia |
Primary Outcome Measures :
- Responders Rate at Week 6 (Pain While Moving) [ Time Frame: Baseline and Week 6 ]The responder rate was defined as the percentage of patients whose pain score while moving during the last 48 hours, measured by means of a 10 cm Visual Analogue Scale (VAS, 0 = no pain, 10 = maximum pain) decreased by at least 50% at Week 6 as compared to baseline. Pain at movement is the cardinal symptom of plantar fasciitis and the 10 cm VAS is a reference method for the assessment of pain intensity.
Secondary Outcome Measures :
- Changes From Baseline in Gerbershagen's Score at Week 18 [ Time Frame: Baseline and Week 18 ]The Gerbershagen scale gives a global score ranging between I and III, with lower scores reflecting less impact of pain in terms of temporal, spatial aspects, drug taking behaviour and utilization of the health care system. The changes in Gerbershagen's global scores from baseline to Week 18 are reported as percentage of patients for each of the specified categories.
- Changes From Baseline in Maximum Pain (Pain While Moving) at Each Visit [ Time Frame: Baseline and Weeks 2, 6, 10, 14 and 18 ]Assessments of the pain intensity while moving (maximum pain during the previous 48 hours) were performed by means of a 10 cm VAS (0 = no pain, 10 = maximum pain) at each visit. The changes from baseline, expressed as Pain Intensity Difference (PID) values at each indicated timepoint are reported.
- Assessment of Sum of Pain Intensity Difference (SPID) for Maximum Pain for Overall Study [ Time Frame: Baseline and Weeks 2, 6, 10, 14 and 18 ]Assessments of the pain intensity while moving (maximum pain during the previous 48 hours) were performed by means of a 10 cm VAS (0 = no pain, 10 = maximum pain) at each visit. The PID values at each timepoint were determined by comparison to baseline, followed by calculation of the area under the curve (AUC) of PID as a function of time (i.e. SPID). The least square (LS) means of SPID, adjusted for the baseline value of pain while moving are reported.
- Changes From Baseline in Continuous Pain (Pain At Rest) at Each Visit [ Time Frame: Baseline and Weeks 2, 6, 10, 14 and 18 ]Assessments of the pain intensity while at rest (continuous pain during the previous 48 hours) were performed by means of a 10 cm VAS (0 = no pain, 10 = maximum pain) at each visit. The changes from baseline, expressed as PID values at each indicated timepoint are reported.
- Assessment of SPID for Continuous Pain for Overall Study [ Time Frame: Baseline and Weeks 2, 6, 10, 14 and 18 ]Assessments of the pain intensity while at rest (continuous pain during the previous 48 hours) were performed by means of a 10 cm VAS (0 = no pain, 10 = maximum pain) at each visit. The PID values at each timepoint were determined by comparison to baseline, followed by calculation of the AUC of PID as a function of time (i.e. SPID). The LS means for SPID, adjusted for the baseline value of pain at rest are reported.
- Changes From Baseline in Pain Threshold at Each Visit [ Time Frame: Baseline and Weeks 2, 6, 10, 14 and 18 ]The maximum pain felt in the medial back foot was measured using an algometer. The pain threshold corresponded to the maximum pressure at which pain was still tolerated. Changes from baseline, expressed as pain threshold differences at each indicated timepoint are reported.
- Assessment of Sum of Pain Threshold Differences (by Measurement of AUC) for Overall Study [ Time Frame: Baseline and Weeks 2, 6, 10, 14 and 18 ]Assessments of the pain threshold using an algometer (which was the pressure corresponding to the maximum tolerated pain) were performed at each visit. Pain threshold differences at each timepoint were determined by comparison to baseline, followed by calculation of the AUC of the pain threshold difference as a function of time. The LS means of AUC, adjusted for the baseline value of pain threshold are reported.
- Changes From Baseline in Pressure Threshold (With Algometer) at Each Visit [ Time Frame: Baseline and Weeks 2, 6, 10, 14 and 18 ]Pressure pain in the medial back foot was measured using an algometer. Pressure threshold corresponded to the minimum pressure causing pain. The changes from baseline, expressed as pressure threshold differences at each indicated timepoint are reported.
- Assessment of Sum of Pressure Threshold Differences (by Measurement of AUC) for Overall Study [ Time Frame: Baseline and Weeks 2, 6, 10, 14 and 18 ]Assessments of the pressure threshold using an algometer (which corresponded to the minimum pressure causing pain) were performed at each visit. Pressure threshold differences at each timepoint were determined by comparison to baseline, followed by calculation of the AUC of the pressure threshold difference as a function of time. The LS means of AUC, adjusted for the baseline value of pressure threshold are reported.
- Assessment of Dorsal Extension / Plantar Flexion Range of Motion (ROM) of the Affected Foot At Week 18 [ Time Frame: Baseline and Week 18 ]Dorsal extension and plantar flexion of the affected foot were assessed at baseline and at Week 18. A ROM of approximately 70 degrees is considered to be normal. The LS means, adjusted for the baseline value are reported.
- Number of Patients Without Pain and/or With a Pain Reduction Based on Global Assessment of Pain by Investigator at Each Visit [ Time Frame: Baseline and Weeks 2, 6, 10, 14 and 18 ]A global assessment of the patient's current condition relative to baseline was performed by the Investigator at each visit using 5 level scale: significantly better, slightly better, unchanged, slightly worse, significantly worse. The number of patients for each variable at each indicated timepoint are reported.
- Number of Patients Without Pain and/or With a Pain Reduction Based on Global Assessment of Pain by Patient at Each Visit [ Time Frame: Baseline and Weeks 2, 6, 10, 14 and 18 ]A global assessment of the patient's current condition relative to baseline was performed by the patient at each visit using a 5 level scale: significantly better, slightly better, unchanged, slightly worse, significantly worse. The number of patients for each variable at each indicated timepoint are reported.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Chronic plantar fasciitis (duration of disorder at least 4 months)
- At least 4 points on the visual analogue scale (0-10) for the most severe pain within the last 48 hours
- At least 2 previous unsuccessful conservative therapies
- Age 18 and older
Exclusion Criteria:
- Rheumatoid diseases (M. Bechterew, chronic polyarthritis, psoriasis-arthritis, para /post-infectious arthritis etc.)
- Previous surgery in the affected area of the foot
- Pre-treatment with Botulinum toxin A (only de novo patients)
- Prohibited concomitant treatment: local injections during the study and 2 weeks prior to start of study
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00447876
Locations
| Germany | |
| University Hospital Charite, Campus Virchow, Musculoskeletal Centre, Orthopedic Clinic | |
| Berlin, Germany, 13353 | |
| Orthopedic Practice Biberburg | |
| Berlin, Germany, 14089 | |
| Orthopedic Practice | |
| Karlsruhe, Germany, 76133 | |
| Klinik für Orthopädie und Rheumatologie, Universitätsklinikum Gießen und Marburg GmbH | |
| Marburg, Germany | |
| Orthocentre Munich | |
| Munich, Germany, 81547 | |
| Orthopedic Practice | |
| Weiden, Germany, 92637 | |
Sponsors and Collaborators
Ipsen
Investigators
| Study Director: | Ipsen Medical Director | Ipsen |
Publications of Results:
| Responsible Party: | Ipsen |
| ClinicalTrials.gov Identifier: | NCT00447876 |
| Other Study ID Numbers: |
A-94-52120-100 2004-002533-39 ( EudraCT Number ) |
| First Posted: | March 15, 2007 Key Record Dates |
| Results First Posted: | June 23, 2017 |
| Last Update Posted: | November 22, 2019 |
| Last Verified: | November 2019 |
Additional relevant MeSH terms:
|
Fasciitis Fasciitis, Plantar Musculoskeletal Diseases Foot Diseases Botulinum Toxins Botulinum Toxins, Type A abobotulinumtoxinA Acetylcholine Release Inhibitors |
Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Cholinergic Agents Neurotransmitter Agents Physiological Effects of Drugs Neuromuscular Agents Peripheral Nervous System Agents |